- Home
- FBP vs KNSA Comparison
FBP vs KNSA Comparison
Compare FBP & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBP | KNSA |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FBP | KNSA |
|---|---|---|
| Price | $23.18 | $56.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $25.50 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.2M | 778.5K |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | 18.78 | ★ 225.00 |
| EPS | ★ 0.57 | 0.27 |
| Revenue | ★ $1,255,034,000.00 | $677,564,000.00 |
| Revenue This Year | $15.10 | $37.48 |
| Revenue Next Year | $4.65 | $17.87 |
| P/E Ratio | ★ $40.89 | $217.15 |
| Revenue Growth | 2.38 | ★ 60.09 |
| 52 Week Low | $19.16 | $25.71 |
| 52 Week High | $24.57 | $59.87 |
Technical Indicators
Market Signals| Indicator | FBP | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 59.85 |
| Support Level | $20.55 | $40.67 |
| Resistance Level | $23.43 | N/A |
| Average True Range (ATR) | 0.47 | 2.59 |
| MACD | -0.20 | 0.27 |
| Stochastic Oscillator | 8.92 | 75.71 |
Price Performance
Historical ComparisonAbout FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Mortgage Banking; Consumer (Retail) Banking; Commercial and Corporate Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. The Consumer (Retail) Banking segment generates the majority of revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.